C-reactive protein kinetics as prognostic biomarkers in advanced melanoma treated with immune checkpoint inhibitors
Melanoma Research,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 8, 2025
C-reactive
protein
(CRP)
kinetics
has
emerged
as
a
potential
biomarker
for
predicting
treatment
response
and
survival
in
various
tumors
treated
with
immune
checkpoint
inhibitors
(ICIs).
However,
data
on
CRP
melanoma
are
limited.
This
study
evaluates
the
relationship
between
kinetic
groups
progression-free
(PFS)
overall
(OS)
104
advanced
patients
ICIs
from
2015
to
2023.
Patients
were
classified
into
four
groups:
flare
responders,
defined
whose
at
least
doubles
within
1
month
then
falls
below
baseline
by
3
months;
decreases
≥30%
months
without
doubling;
all-normal
CRP,
remains
upper
limit
of
normal
throughout
first
nonresponders,
who
do
not
meet
these
criteria.
Amongst
patients,
64.4%
received
anti-programmed
death-1
monotherapy
35.6%
nivolumab-ipilimumab
combination.
Median
PFS
was
4.80
10.90
8.83
responders
33.57
(
P
<
0.001).
Similarly,
median
OS
11.9
38.1
21.5
54.5
Multivariate
analysis
confirmed
an
independent
predictor
PFS,
objective
response.
classification
is
simple
prognostic
tool
associated
improved
outcomes,
underscoring
clinical
value
monitoring.
Язык: Английский
Clinical Application of ImmunoPET Targeting Checkpoint Inhibitors
Cancers,
Год журнала:
2023,
Номер
15(23), С. 5675 - 5675
Опубликована: Ноя. 30, 2023
In
the
last
decade,
monoclonal
antibodies
(mAbs)
targeting
CTLA-4,
PD-1,
or
PD-L1
have
been
developed
and
immune
checkpoint
inhibitors
(ICIs)
become
main
approach
in
cancer
immunotherapy.
However,
not
all
patients
benefit
from
ICI
therapy
some
are
at
risk
of
developing
treatment-induced
side-effects.
These
aspects,
parallel
with
imaging
challenges
related
to
response
assessments
during
immunotherapy,
driven
scientific
research
discovery
new
predictive
biomarkers
individualize
who
could
ICIs.
this
context,
molecular
using
PET
(positron
emission
tomography),
which
allows
for
whole-body
tumor
visualization,
may
be
a
promising
non-invasive
method
determination
patients’
sensitivity
antibody
drugs.
Several
tracers,
diverse
2-[18F]FDG
(or
2-Deoxy-2-[18F]fluoroglucose),
image
checkpoints
(ICs)
key
elements
system,
although
most
them
still
preclinical
phases.
Herein,
we
present
current
state
ImmunoPET-targeting
IC
proteins
mAbs
fragments,
focus
on
latest
developments
clinical
studies
solid
tumors.
Moreover,
given
relevance
system
tumor-infiltrating
lymphocytes
particular
prediction
ICIs,
dedicate
portion
review
T
cells.
Язык: Английский
Metabolic Profiling to Assess Response to Targeted and Immune Therapy in Melanoma
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(3), С. 1725 - 1725
Опубликована: Янв. 31, 2024
There
is
currently
no
consensus
to
determine
which
advanced
melanoma
patients
will
benefit
from
targeted
therapy,
immunotherapy,
or
a
combination
of
both,
highlighting
the
critical
need
identify
early-response
biomarkers
therapy.
The
goal
this
review
provide
scientific
rationale
highlight
potential
role
metabolic
imaging
assess
response
and/or
immune
therapy
in
cancer.
For
that
purpose,
brief
overview
current
treatments
provided.
Then,
knowledge
with
respect
metabolism
described
an
emphasis
on
major
crosstalks
between
cell
and
signaling
pathways
involved
BRAF-targeted
as
well
checkpoint
inhibition
therapies.
Finally,
preclinical
clinical
studies
using
profiling
treatment
are
summarized
particular
focus
PET
(Positron
Emission
Tomography)
13C-MRS
(Magnetic
Resonance
Spectroscopy)
methods.
Язык: Английский
Positron Emission Tomography/Computed Tomography Transformation of Oncology
Sze-Ting Lee,
Natalia N. Kovaleva,
Clare Senko
и другие.
PET Clinics,
Год журнала:
2024,
Номер
19(2), С. 231 - 248
Опубликована: Янв. 16, 2024
Язык: Английский
Targeting anticancer immunity in melanoma tumor microenvironment: Unleashing the potential of adjuvants, drugs, and phytochemicals
Journal of drug targeting,
Год журнала:
2024,
Номер
32(9), С. 1052 - 1072
Опубликована: Июль 23, 2024
Melanoma
poses
a
challenge
in
oncology
because
of
its
aggressive
nature
and
limited
treatment
modalities.
The
tumour
microenvironment
(TME)
melanoma
contains
unique
properties
such
as
an
immunosuppressive
high-density
environment,
unusual
vasculature,
high
number
stromal
cells.
In
recent
years,
numerous
experiments
have
focused
on
boosting
the
immune
system
to
effectively
remove
malignant
Adjuvants,
consisting
phytochemicals,
toll-like
receptor
(TLR)
agonists,
cytokines,
shown
encouraging
results
triggering
antitumor
immunity
augmenting
therapeutic
effectiveness
anticancer
therapy.
These
adjuvants
can
stimulate
maturation
dendritic
cells
(DCs)
infiltration
cytotoxic
CD8+
T
lymphocytes
(CTLs).
Furthermore,
nanocarriers
help
deliver
immunomodulators
antigens
directly
stroma,
thereby
improving
their
efficacy
against
remodelling
TME
utilising
other
be
combined
with
current
modalities
for
therapy
outcomes.
This
review
article
explores
potential
adjuvants,
drugs,
nanoformulations
enhancing
potency
macrophages,
CTLs,
natural
killer
(NK)
Additionally,
capacity
these
agents
repress
function
components
TME,
subsets
myeloid
will
discussed.
Язык: Английский
Prospective Assessment of Fluorine-18-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) for Early Identification of Checkpoint-Inhibitor-Induced Pseudoprogression
Sif Homburg,
Charlotte Birk Christensen,
Magnus Pedersen
и другие.
Cancers,
Год журнала:
2024,
Номер
16(5), С. 964 - 964
Опубликована: Фев. 27, 2024
The
activity
of
immune
checkpoint
inhibitors
(ICIs)
in
patients
with
metastatic
melanoma
is
often
monitored
using
fluorine-18-fluorodeoxyglucose-positron
emission
tomography/computed
tomography
(FDG-PET/CT)
scans.
However,
distinguishing
disease
progression
(PD)
from
pseudoprogression
(PsPD),
where
increased
FDG
uptake
might
reflect
cell
rather
than
tumor
growth,
remains
a
challenge.
This
prospective
study
compared
the
efficacy
dual-time
point
(DTP)
FDG-PET/CT
modified
response
criteria
(PERCIMT)
differentiating
PsPD
PD.
From
July
2017-January
2021,
41
suspected
to
have
on
an
evaluation
scan
were
prospectively
included
(29
evaluable).
A
subsequent
DTP
was
conducted
within
14
days,
followed
by
confirmatory
scan.
Additionally,
PERCIMT
applied.
identified
24%
and
76%
Applying
criteria,
69%
showed
PsPD,
while
31%
had
On
follow-up,
10
(34%)
demonstrated
confirmed
19
(66%)
exhibited
sensitivity
specificity
20%
74%,
respectively,
for
this
80%
37%,
respectively.
Our
findings
suggest
limited
PD
ICI-treated
melanoma.
use
could
complement
clinical
assessment
be
incorporated
multidisciplinary
team
conferences
enhanced
decision-making.
Язык: Английский
Clinical and Imaging Follow-Up for High-Risk Cutaneous Melanoma: Current Evidence and Guidelines
Cancers,
Год журнала:
2024,
Номер
16(14), С. 2572 - 2572
Опубликована: Июль 18, 2024
The
most
recent
(eighth)
edition
of
the
American
Joint
Committee
on
Cancer
(AJCC)
staging
system
divides
invasive
cutaneous
melanoma
into
two
broad
groups:
“low-risk”
(stage
IA–IIA)
and
“high-risk”
IIB–IV).
While
surveillance
imaging
for
high-risk
patients
makes
intuitive
sense,
supporting
data
are
limited
in
that
they
mostly
respective
used
varying
methods,
schedules,
endpoints.
As
a
result,
there
is
lack
uniformity
across
different
dermatologic
oncologic
organizations
regarding
recommendations
follow-up,
especially
imaging.
That
said,
bulk
retrospective
prospective
support
follow-up
patients.
Currently,
it
seems
either
positron
emission
tomography
(PET)
or
whole-body
computerized
(CT)
reasonable
options
with
brain
magnetic
resonance
(MRI)
preferred
detection
metastases
who
can
undergo
it.
current
era
effective
systemic
therapies
(ESTs),
which
improve
disease-free
survival
(DFS)
overall
(OS)
beyond
lead-time
bias,
has
emphasized
role
detecting
various
patterns
EST
response
treatment
relapse,
as
well
importance
radiologic
tumor
burden.
Язык: Английский
Molecular Imaging of Melanoma VEGF-expressing Tumors through [99mTc]Tc-HYNIC-Fab(Bevacizumab)
Anti-Cancer Agents in Medicinal Chemistry,
Год журнала:
2024,
Номер
24(18), С. 1347 - 1359
Опубликована: Авг. 12, 2024
Angiogenesis
is
a
process
that
many
tumors
depend
on
for
growth,
development,
and
metastasis.
Vascular
endothelial
growth
factor
(VEGF)
one
of
the
major
players
in
tumor
angiogenesis
several
types,
including
melanoma.
VEGF
inhibition
achieved
by
bevacizumab,
humanized
monoclonal
antibody
binds
with
high
affinity
to
prevents
its
function.
In
order
successfully
enable
vivo
expression
imaging
murine
melanoma
model,
we
previously
labeled
bevacizumab
[
Язык: Английский